Spherix Global Insights Reports Persistent High Unmet Need in Europe's Evolving MASH Market

Survey results show ~75% of gastroenterologists and hepatologists report high unmet need for MASH therapies, but patient access to approved treatments remains limited. The gap suggests commercialization and treatment adoption headwinds despite strong demand. Overall implications are modest near-term for markets absent specific company/regulatory catalysts.

Analysis

This reads less like a demand shock and more like evidence that commercialization risk in MASH is still dominated by payer friction and care-pathway bottlenecks. In the next 1-3 months, the market is likely to overreact to every physician sentiment datapoint, but the real limiter is whether patients can actually be identified, staged, and approved at scale; that keeps early revenue concentrated in a narrow hepatology channel and raises the bar for any pure-play launch.

The relative winners are likely to be broader cardiometabolic platforms rather than liver-only franchises. Companies with established obesity/diabetes distribution and primary-care reach can translate a MASH narrative into a much larger commercial funnel, while specialist-only names risk a slower-than-model adoption curve and multiple compression if script growth lags enthusiasm.

Contrarian take: consensus may be treating "high unmet need" as equivalent to fast uptake, but in MASH those are very different variables. Unmet need supports a multi-year addressable market, yet access constraints can keep realized sales below Street expectations for several quarters; what would change that is a material expansion in coverage, simplified diagnostic pathways, or a cleaner label/health-economics case. The main falsifier for a bearish commercialization view is evidence that prior-auth friction is easing and new starts are accelerating on a sustained basis rather than a one-off channel fill.

Key Decisions for Investors

• Prefer LLY and NVO over pure-play MASH exposure over the next 3-6 months; if MASH adoption stays access-constrained, the large-cap metabolic franchises should capture the broader value pool with less launch risk.
• Avoid initiating or add only on weakness in MDGL until payer coverage and net-new start data improve; use the next quarterly script update as the key checkpoint. If coverage expansion fails to offset prior-auth friction, the stock is vulnerable to another leg of multiple compression.
• If you want a relative-value expression, pair long LLY / short MDGL for the next 1-3 months: long the company with PCP distribution and multiple shots on goal, short the name most exposed to a slow reimbursement ramp.
• Set an alert on MASH reimbursement and access metrics: a sustained increase in covered lives or a step-up in prescription conversion would falsify the cautious view and justify rotating back into the pure-play names.